1417318-27-4
1417318-27-4
Chemical Structure
Utomilumab
Synonym(s): PF 05082566
- CAS No.: 1417318-27-4
- Formula:N/A
- Molecular Weight:(142.78 kDa)
SMILES: [Utomilumab]
Biological Activity: Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20+ non-Hodgkin lymphomas[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Utomilumab | 99.33% | Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20+ non-Hodgkin lymphomas. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Anthony W Tolcher, et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Sep 15;23(18):5349-5357. [Content Brief]
- [2]. Ajay K Gopal, et al. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534. [Content Brief]
- [3]. Rose D, et al. 1258 PBMC humanized mouse model with clinical relevance in assessing the safety profile of 4–1BB agonists utomilumab and urelumab. 2022.
Keywords
